Economic evaluation of camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma in the United States and China

作者：Jingxuan Wei, Kai Xu, Yingtao Lin, Qiang Liu, Chongchong Zhou, Pei Zhang, Rui Ma, Mengdie Zhang, Lingli Zhang, Xin Li · 发表于：International Journal of Clinical Pharmacy · 年份：2024 · DOI：10.1007/s11096-024-01752-8 · 被引用次数：16 · 研究领域：Hepatocellular Carcinoma Treatment and Prognosis、Economic and Financial Impacts of Cancer、Cancer Immunotherapy and Biomarkers